Melanoma Stage III

The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma